PONTE VEDRA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing SpeedPlate™ MicroQuad™ implants. The MicroQuad™ implant expands upon the broad utility of the SpeedPlate™ platform, which is ...

Core Insights - Treace Medical Concepts has successfully completed the first cases using IntelliGuide™ PSI technology with the Adductoplasty® System for personalized correction of midfoot deformities [1][2] - IntelliGuide™ PSI is the first patient-specific cut guide system in the U.S. for bunion and midfoot deformities, utilizing AI to create a pre-operative surgical plan from CT scans [2] - The company plans to progressively expand access to IntelliGuide™ for both Lapiplasty® and Adductoplasty® procedures, with a full market release expected in the first half of 2025 [2] Company Overview - Treace Medical Concepts focuses on advancing surgical treatment standards for bunions and related midfoot deformities, affecting approximately 67 million Americans, with an estimated 1.1 million being surgical candidates annually [6][7] - The company has developed the Lapiplasty® 3D Bunion Correction® System, which addresses all three planes of bunion deformities and secures the unstable joint [7] - Treace has also introduced the Adductoplasty® Midfoot Correction System and SpeedPlate™ Rapid Compression Implants to enhance surgical correction and fixation across various procedures [7] Market Position and Future Plans - The introduction of IntelliGuide™ PSI is expected to strengthen Treace's market leadership in the surgical management of bunion and midfoot deformities [3] - The company aims to build a comprehensive portfolio of digital technologies to meet the evolving needs of surgeons and patients [3] - Surgeons have expressed optimism about the potential of IntelliGuide™ PSI to revolutionize treatment approaches for complex foot deformities [3]

Core Viewpoint - Treace Medical Concepts, Inc. has appointed Guy Guglielmino as Chief Commercial Officer to lead its commercial efforts and drive innovation, product commercialization, and growth in the surgical treatment of bunions and midfoot deformities [1][2]. Company Overview - Treace Medical Concepts is focused on advancing the standard of care for surgical management of bunions and related midfoot deformities, which affect approximately 67 million Americans, with an estimated 1.1 million being annual surgical candidates [5]. - The company has developed the Lapiplasty® 3D Bunion Correction® System, which addresses the root cause of bunions by correcting deformities in all three planes and securing the unstable joint [5]. - Treace has also introduced the Adductoplasty® Midfoot Correction System for surgical correction of midfoot deformities and the SpeedPlate™ Rapid Compression Implants for various bone fusion procedures [5][6]. Leadership Appointment - Guy Guglielmino brings extensive experience in the medical technology industry, having previously served as President of Recovery Sciences at Enovis and held senior marketing roles at other notable companies [2]. - His appointment is expected to enhance Treace's market growth and innovation capabilities, aligning with the company's mission to meet customer needs and establish new market standards [2].

Core Insights - Treace Medical Concepts, Inc. is participating in the Stifel 2024 Healthcare Conference with a fireside chat featuring CEO John T. Treace and CFO Mark L. Hair on November 19, 2024 [1] Company Overview - Treace Medical Concepts is focused on advancing surgical treatment for bunions and related midfoot deformities, impacting approximately 67 million Americans, with an estimated 1.1 million being annual surgical candidates [4] - The company has developed the patented Lapiplasty® 3D Bunion Correction® System, which addresses the root cause of bunions by correcting deformities in three planes and stabilizing the affected joint [4] - Treace has also introduced the Adductoplasty® Midfoot Correction System for surgical correction of midfoot deformities and the SpeedPlate™ Rapid Compression Implants for versatile fixation across various procedures [4]

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.41%. A quarter ago, it was expected that this orthopedic medical device maker would post a loss of $0.29 per share when it actually produced a loss of $0.34, delivering a surprise of -17.24%.Over the last four qu ...

PONTE VEDRA, Fla., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Revenue of $45.1 million in third quarter 2024 increased 11% over same period in 2023Third qua ...

LOS ANGELES, Oct. 23, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ: TMCI) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.If you are a shareholder who suffered a loss, click here to participat ...

PONTE VEDRA, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Tuesday, November 5, 2024. Company management will host a conference call to d ...

Core Viewpoint - Treace Medical Concepts, Inc. has filed a lawsuit against Stryker Corporation and its subsidiary Wright Medical Technology, alleging infringement of 9 patents related to its Lapiplasty® 3D Bunion Correction® technologies and unfair competition [1][2]. Company Overview - Treace Medical Concepts is a medical technology company focused on advancing the surgical treatment of bunions and related midfoot deformities, with its flagship products being the Lapiplasty® and Adductoplasty® Procedures [1][4]. - The company estimates that approximately 67 million Americans are affected by bunions, with around 1.1 million being annual surgical candidates [4]. Patent and Legal Actions - The lawsuit seeks injunctive relief and damages, emphasizing Treace's commitment to protecting its intellectual property and investments in research and technology [1][2]. - Treace claims to be the first company to develop and patent an instrumented 3D bunion correction system, which has established a new segment in the US bunion market [2]. Financial Expectations - The company anticipates a 50% improvement in Adjusted EBITDA for 2024 compared to the full-year 2023 and expects to reach Adjusted EBITDA breakeven in 2025 [2].

PONTE VEDRA, Fla., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies at the American Orthopaedic Foot & Ankle Societ ...